Paraflu Study
Purpose: The Clinical Core has initiated a pilot study of 2 novel FDA approved compounds, fluconazole and paroxetine, for the treatment of HIV-associated neurocognitive disorders (HAND), which show significant neuroprotection in our in vitro model system and also a potent anti-inflammatory effect in our SIV Model.
Contact: 443-799-7241
NIH Study Report
Neurologic AIDS Research Consortium – 1) International Project - HIV Dementia in Uganda: Response to Highly Active Antiretroviral Therapy – Leadership Award
The major goal of this project is to determine whether highly active antiretroviral therapy improves neuropsychological test performance among HIV+ individuals in Uganda with cognitive impairment.



